scholarly journals Pharmaceutical Prices: The Impact of the Launch Strategy - An Analysis of German Data

2019 ◽  
Author(s):  
Yvonne-Beatrice Böhler ◽  
Christian Lamping ◽  
Philipp C. Wichardt
Pharmacy ◽  
2020 ◽  
Vol 9 (1) ◽  
pp. 1
Author(s):  
Kah Seng Lee ◽  
Yaman Walid Kassab ◽  
Nur Akmar Taha ◽  
Zainol Akbar Zainal

Increasing prescription drug pricing often reflects additional work stress on medical professionals because they function as financial advisors for patients and help them manage out-of-pocket expenses. Providers or prescribers wish to help patients with prescription costs but often lack related information. Healthcare plan providers try to display prescription and drug cost information on their websites, but such data may not be linked to electronic prescription software. A mark-up is defined as the additional charges and costs that are applied to the price of a product for the purpose of covering overhead costs, distribution charges, and profit. Therefore, the policies implemented in the pharmaceutical distribution chain might include the regulation of wholesale and retails mark-ups and pharmaceutical remuneration. If mark-ups are regulated, countries are highly recommended to use regressive mark-ups rather than fixed percentage mark-ups. This narrative review provides insights into the framework of pharmaceutical mark-up systems by describing different factors impacting pharmaceutical prices and affordability. These include the interplay of medicine pricing and the supply chain, the impact of pertinent laws and regulation and out-of-pocket expenditure.


2013 ◽  
Vol 16 (7) ◽  
pp. A455 ◽  
Author(s):  
C. Genane ◽  
G. Marinoni ◽  
G. Ando ◽  
F. Reinaud

2018 ◽  
Vol 48 (1) ◽  
pp. 79-92 ◽  
Author(s):  
G. Kovács ◽  
T. Almási ◽  
A. Millier ◽  
M. Toumi ◽  
M. Horváth ◽  
...  

AbstractPurposeTo provide an overview on the magnitude of the impact of schizophrenia on the healthcare system in Europe and to gain a better understanding on the most important factors influencing the variation of costs.MethodsStudies reporting costs and healthcare utilization among patients with schizophrenia were searched in MEDLINE (via Scopus), EMBASE (via Scopus) and Cochrane Database of Systematic Reviews on 19th January 2017.ResultsTwenty-three studies, from the 1075 references initially identified, were included in this review. The annual cost per patient ranged from €533 in Ukraine to €13,704 in the Netherlands. Notably drug costs contributed to less than 25% of the direct healthcare cost per patient in every country, which might be explained by similar pharmaceutical prices among countries due to the reference pricing system applied in Europe. Inpatient costs were the largest component of health service costs in the majority of the countries. Despite methodological heterogeneity across studies, four major themes could be identified (age, severity of symptoms, continuation of treatment/persistence, hospitalization) that have substantial impact on the costs of schizophrenia.ConclusionsSchizophrenia represents a substantial cost for the healthcare system in Europe driven by the high cost per patient. Substantial savings could potentially be achieved by increasing investment in the following areas: (1) reducing the number of hospitalizations e.g. by increasing the efficiency of outpatient care; (2) working out interventions targeted at specific symptoms; (3) improving patient persistence and adherence in antipsychotic therapy.


Author(s):  
Stuart O. Schweitzer ◽  
Z. John Lu

This chapter provides a detailed examination of pharmaceutical pricing strategies in the United States. It points out that pharmaceutical expenditure as a share of total healthcare spending has historically been quite low in comparison to that of hospitalization and physician services. It identifies several common measures of pharmaceutical prices, and highlights the difference in conclusions reached based on different measures. It offers a critical review of several models used to explain pharmaceutical price behavior, which are grouped into three major categories: market structure models, R&D cost-based models, and product quality or value based models. The chapter concludes that prices of brand-name drugs in the United States are largely driven by product quality attributes, not cost of R&D. Lastly, the chapter examines the impact of generic entry on price.


2008 ◽  
pp. 12-30 ◽  
Author(s):  
E. Gurvich ◽  
V. Sokolov ◽  
A. Ulyukaev

The article presents an empirical investigation of the impact of the Balassa-Samuelson effect on the real ruble appreciation in 1999-2007. We consider long-run, supply-side determinants of the real ruble exchange rate, such as changes in terms of trade and labor productivity. Using Russian and German data on price and productivity differentials between tradable and non-tradable sectors of the two economies, we estimate the significance of oil price shocks and the Balassa-Samuelson effect for the real ruble appreciation. Our study demonstrates that, on average, about 1/3 of the observed appreciation can be attributed to the Balassa-Samuelson effect. The cointegrating relationship between the productivity differential and the real exchange rate provides evidence of the healthy nature of the economic growth, which took place in Russia during the time period under investigation. These findings suggest that exchange rate adjustments should be used by the Central Bank of Russia mainly as a monetary policy instrument for fighting inflation rather than as a tool for competitive devaluations.


2014 ◽  
Vol 17 (3) ◽  
pp. A19-A20
Author(s):  
O. Mohamed ◽  
D. Kreling

2013 ◽  
Vol 372 ◽  
pp. 538-542
Author(s):  
Guo Zhong Jia ◽  
Xin Ping Wu ◽  
Zhen Hua Jia

According to the special structure of DCT, the control strategy of launch with two clutches has been proposed to share the friction work and extend the life of both clutches. The dynamic model of launch with two clutches and the clutch control model have been built. the control strategies of both clutches have been proposed respectively according to the requirement of the different driver intention and the limitation of the impact of vehicle. The simulation model of launch with two clutches has been built using the Matlab/Simulink platform, and the simulation has been carried out. The Simulation results show that the balance of friction work based on this launch strategy with two clutches has been validated.


2019 ◽  
Vol 82 (S 02) ◽  
pp. S131-S138
Author(s):  
Sebastian Bartholomäus ◽  
Yannik Siegert ◽  
Hans Werner Hense ◽  
Oliver Heidinger

Abstract Background The evaluation of population-based screening programs, like the German Mammography Screening Program (MSP), requires collection and linking data from population-based cancer registries and other sources of the healthcare system on a case- specific level. To link such sensitive data, we developed a method that is compliant with German data protection regulations and does not require written individual consent. Methods Our method combines a probabilistic record linkage on encrypted identifying data with ‘blinded anonymisation’. It ensures that all data either are encrypted or have a defined and measurable degree of anonymity. The data sources use a software to transform plain-text identifying data into a set of irreversibly encrypted person cryptograms, while the evaluation attributes are aggregated in multiple stages and are reversibly encrypted. A pseudonymisation service encrypts the person cryptograms into record assignment numbers and a downstream data-collecting centre uses them to perform the probabilistic record linkage. The blinded anonymisation solves the problem of quasi-identifiers within the evaluation data. It allows selecting a specific set of the encrypted aggregations to produce data export with ensured k-anonymity, without any plain-text information. These data are finally transferred to an evaluation centre where they are decrypted and analysed. Our approach allows creating several such generalisations, with different resulting suppression rates allowing dynamic balance information depth with privacy protection and also highlights how this affects data analysability. Results German data protection authorities approved our concept for the evaluation of the impact of the German MSP on breast cancer mortality. We implemented a prototype and tested it with 1.5 million simulated records, containing realistically distributed identifying data, calculated different generalisations and the respective suppression rates. Here, we also discuss limitations for large data sets in the cancer registry domain, as well as approaches for further improvements like l-diversity and how to reduce the amount of manual post-processing. Conclusion Our approach enables secure linking of data from population-based cancer registries and other sources of the healthcare system. Despite some limitations, it enables evaluation of the German MSP program and can be generalised to be applicable to other projects.


2020 ◽  
Vol 29 (S1) ◽  
pp. 47-62
Author(s):  
Simona Gamba ◽  
Paolo Pertile ◽  
Sabine Vogler

Sign in / Sign up

Export Citation Format

Share Document